1. Pink Sheet
  2. >>Archive

Auxilium Buys Actient As Base Business Weakens

 
• By Jessica Merrill

The acquisition will establish Auxilium as a leading urology company and add nine commercial products. But the $585 million upfront acquisition price is expensive for Auxilium, as sales of its own products slump.

Auxilium Pharmaceuticals Inc. will establish itself as a leading urology company with the acquisition of Actient Holdings LLC for $585 million upfront plus contingency payments, the specialty pharma announced April 29. The acquisition, which closed April 26, comes as sales of Auxilium’s own products slowed in the first quarter, including Testim testosterone gel and Xiaflex (collagenase clostridium histolyticum) for Dupuytren’s contracture.

The acquisition of privately-held Actient will add nine commercial products to Auxilium’s portfolio, four of which are in the urology space and currently on the market. Actient generated $125 million...

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.